Lurbinectedin Monotherapy Improves ORR in Relapsed SCLC .

Gina Columbus 

Published: Monday, Mar 25, 2019

Lurbinectedin as Monotherapy was found to show an improvement in Objective Response rate (ORR) in Patients with Relapsed Small Cell Lung Cancer (SCLC), meeting the primary endpoint of a phase II trial by both investigator review and an independent review committee .

The updated phase II findings are slated to be presented at an upcoming medical meeting, announced PharmaMar, the manufacturer of the investigational RNA polymerase II inhibitor. ...